Companies:
50,705
Total Market Cap:
148173845241549.37
Global Rank
#4464
Country Rank
#47
Market Cap
3.59 B
Price
52.65
Change (%)
10.84%
Volume
17.21 M
uniQure N.V.'s latest marketcap:
3.59 B
As of 09/26/2025, uniQure N.V.'s market capitalization has reached $3.59 B. According to our data, uniQure N.V. is the 4464th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.59 B |
| Revenue (ttm) | 14.34 M |
| Net Income (ttm) | -198,995,000 |
| Shares Out | 68.1 M |
| EPS (ttm) | -3.85 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/04/2025 |
Market Cap Chart
Data Updated: 09/26/2025
uniQure N.V.'s yearly market capitalization.
uniQure N.V. has seen its market value grow from $603.4 M to $3.59 B since 2017, representing a total increase of 494.23% and an annual compound growth rate (CAGR) of 25.88%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 09/26/2025 | $3.59 B | -12.93% | 4464 |
| 12/31/2024 | $860.8 M | 165.93% | 9617 |
| 12/29/2023 | $323.7 M | -69.5% | 15964 |
| 12/30/2022 | $1.06 B | 10.73% | 7968 |
| 12/31/2021 | $958.5 M | -40.38% | 9568 |
| 12/31/2020 | $1.61 B | -48.57% | 6074 |
| 12/31/2019 | $3.13 B | 190.93% | 3388 |
| 12/31/2018 | $1.07 B | 78.06% | 5915 |
| 12/29/2017 | $603.4 M | 9477 |
Company Profile
About uniQure N.V.
uniQure N.V. is a biotechnology company dedicated to developing innovative treatments for rare and severe diseases, primarily serving patients in the United States.
Key Products & Pipeline
- HEMGENIX: A groundbreaking therapy enabling hemophilia B patients to produce factor IX, reducing bleeding risks.
- AMT-130: A gene therapy candidate in Phase I/II clinical trials for Huntington’s disease.
- AMT-260: Currently in Phase I/IIa trials for mesial temporal lobe epilepsy.
- AMT-162: In Phase I/IIa trials targeting superoxide dismutase enzyme-amyotrophic lateral sclerosis (ALS).
- AMT-191: An investigational gene therapy in Phase I/IIa trials for Fabry disease.
Strategic Collaborations
- Licensing agreement with Apic Bio to develop gene therapies for ALS caused by SOD-1 mutations.
- Development and commercial supply partnership with CLS Bhering.
Founded in 1998, uniQure N.V. is headquartered in Amsterdam, the Netherlands.
Frequently Asked Questions
-
What is uniQure N.V.'s (QURE) current market cap?As of 09/26/2025, uniQure N.V. (including the parent company, if applicable) has an estimated market capitalization of $3.59 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does uniQure N.V. (QURE) rank globally by market cap?uniQure N.V. global market capitalization ranking is approximately 4464 as of 09/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.